v3.26.1
Segment Information (Details)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
USD ($)
segment
Dec. 31, 2024
USD ($)
Segment Reporting [Abstract]    
Number of operating segments | segment 1  
Number of reportable segments | segment 1  
Segment Reporting, Asset Reconciling Item [Line Items]    
Revenue $ 15,000 $ 0
Non-program specific expenses:    
General and administrative expenses (50,468) (50,811)
Share-based compensation (30,962) (33,546)
Interest income 20,527 14,016
Interest expense (11,459) (10,090)
Loss on extinguishment of debt 0 (34,097)
Income tax (expense) benefit (1,819) (2,844)
Consolidated net loss (197,532) (235,757)
Reportable Segment    
Segment Reporting, Asset Reconciling Item [Line Items]    
Revenue 15,000 0
Less:    
cleminorexton (78,479) (31,876)
Other Orexin program expenses 50,969 9,567
LockBody technology platform expenses (11,970) (10,886)
Discontinued R&D program expenses (3,698) (90,261)
Non-program specific expenses:    
Personnel expenses (29,932) (21,580)
Research tax incentives 22,669 30,942
Other internal R&D expenses (4,260) (2,149)
General and administrative expenses (35,091) (32,132)
Share-based compensation (30,962) (33,546)
Interest income 20,527 14,016
Interest expense (11,459) (10,090)
Loss on extinguishment of debt 0 (34,097)
Other segment items 2,911 (1,687)
Income tax (expense) benefit (1,819) (2,844)
Consolidated net loss $ (197,532) $ (235,757)